Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yan Tu

Showing results (261-270 of 321) with videos related to

Pageof 33
Sort By:
Frontiers in Oncology|December 28, 2020
Complex ALK Fusions Are Associated With Better Prognosis in Advanced Non-Small Cell Lung CancerJin Kang, Xu-Chao Zhang, Hua-Jun Chen, et al.
Lung Cancer (Amsterdam, Netherlands)|April 28, 2019
A molecular graded prognostic assessment (molGPA) model specific for estimating survival in lung cancer patients with leptomeningeal metastasesKai Yin, Yang-Si Li, Mei-Mei Zheng, et al.
Clinical Lung Cancer|December 25, 2024
PEARL: A Multicenter Phase 2 Study of Lorlatinib in Patients with ALK-Rearranged NSCLC and Central Nervous System DiseaseChang Lu, Hong-Hong Yan, Chan-Yuan Zhang, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 20, 2019
Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical TrialYi-Long Wu, Shun Lu, Ying Cheng, et al.
Clinical Lung Cancer|October 12, 2015
Anaplastic Lymphoma Kinase Variants and the Percentage of ALK-Positive Tumor Cells and the Efficacy of Crizotinib in Advanced NSCLCYuan-Yuan Lei, Jin-Ji Yang, Xu-Chao Zhang, et al.
Cancers|January 8, 2023
Longitudinal Plasma Proteomics-Derived Biomarkers Predict Response to MET Inhibitors for MET-Dysregulated NSCLCGuang-Ling Jie, Lun-Xi Peng, Mei-Mei Zheng, et al.
European Journal of Cancer (Oxford, England : 1990)|April 21, 2021
Clinical outcomes of non-small cell lung cancer patients with leptomeningeal metastases after immune checkpoint inhibitor treatmentsMei-Mei Zheng, Hai-Yan Tu, Jin-Ji Yang, et al.
Experimental Hematology & Oncology|November 11, 2021
MET amplification identified by next-generation sequencing and its clinical relevance for MET inhibitorsLun-Xi Peng, Guang-Ling Jie, An-Na Li, et al.
Journal of Genetics and Genomics = Yi Chuan Xue Bao|November 12, 2015
Integrative Analyses of Lung Squamous Cell Carcinoma in Ten Chinese Patients with Transcriptome SequencingLu-Lu Yang, Xu-Chao Zhang, Shao-Kun Chuai, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 12, 2017
Genetic and Immune Profiles of Solid Predominant Lung Adenocarcinoma Reveal Potential Immunotherapeutic StrategiesZhong-Yi Dong, Chao Zhang, Yu-Fa Li, et al.
Pageof 33

Showing results (261-270 of 321) with videos related to

Sort By:
Pageof 33
Frontiers in Oncology|December 28, 2020
Complex ALK Fusions Are Associated With Better Prognosis in Advanced Non-Small Cell Lung CancerJin Kang, Xu-Chao Zhang, Hua-Jun Chen, et al.
Lung Cancer (Amsterdam, Netherlands)|April 28, 2019
A molecular graded prognostic assessment (molGPA) model specific for estimating survival in lung cancer patients with leptomeningeal metastasesKai Yin, Yang-Si Li, Mei-Mei Zheng, et al.
Clinical Lung Cancer|December 25, 2024
PEARL: A Multicenter Phase 2 Study of Lorlatinib in Patients with ALK-Rearranged NSCLC and Central Nervous System DiseaseChang Lu, Hong-Hong Yan, Chan-Yuan Zhang, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 20, 2019
Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical TrialYi-Long Wu, Shun Lu, Ying Cheng, et al.
Clinical Lung Cancer|October 12, 2015
Anaplastic Lymphoma Kinase Variants and the Percentage of ALK-Positive Tumor Cells and the Efficacy of Crizotinib in Advanced NSCLCYuan-Yuan Lei, Jin-Ji Yang, Xu-Chao Zhang, et al.
Cancers|January 8, 2023
Longitudinal Plasma Proteomics-Derived Biomarkers Predict Response to MET Inhibitors for MET-Dysregulated NSCLCGuang-Ling Jie, Lun-Xi Peng, Mei-Mei Zheng, et al.
European Journal of Cancer (Oxford, England : 1990)|April 21, 2021
Clinical outcomes of non-small cell lung cancer patients with leptomeningeal metastases after immune checkpoint inhibitor treatmentsMei-Mei Zheng, Hai-Yan Tu, Jin-Ji Yang, et al.
Experimental Hematology & Oncology|November 11, 2021
MET amplification identified by next-generation sequencing and its clinical relevance for MET inhibitorsLun-Xi Peng, Guang-Ling Jie, An-Na Li, et al.
Journal of Genetics and Genomics = Yi Chuan Xue Bao|November 12, 2015
Integrative Analyses of Lung Squamous Cell Carcinoma in Ten Chinese Patients with Transcriptome SequencingLu-Lu Yang, Xu-Chao Zhang, Shao-Kun Chuai, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 12, 2017
Genetic and Immune Profiles of Solid Predominant Lung Adenocarcinoma Reveal Potential Immunotherapeutic StrategiesZhong-Yi Dong, Chao Zhang, Yu-Fa Li, et al.
Pageof 33